

Note d'application

## Use of Predicted Versus Measured CCS Values from Different Instrument Platforms, and Isomer Separation on the SELECT SERIES Cyclic IMS

---

David Higton, Christian Lanshoeft, Frederic Lozac'h

Waters Corporation, Novartis Pharma AG

---

### Abstract

Biotransformation activities require the comparison of metabolites across species and studies. In general, chromatographic retention time, accurate mass measurement, and mass spectral data are used to align metabolites. Isomeric metabolite comparison may be more challenging particularly when retention times may differ depending on the analytical conditions used. Additionally, the elemental formulae as well as tandem mass spectrometry (MS/MS) spectra can be identical which significantly increases the complexity of the data interpretation and localization of the biotransformation. The use of collision cross section (CCS) values to compare metabolites analyzed using the SELECT SERIES Cyclic IMS and the SYNAPT G2-Si QToF instruments located in different facilities has been shown here and demonstrates the benefit of this analyte-specific physicochemical property to align metabolites across studies.

Moreover, computational prediction of CCS values may provide an additional data asset, allowing the comparison of predicted with measured CCS values. This can further provide additional insights to differentiate between

---

isomers. The prediction can also be used to suggest when additional cyclic ion mobility separation (cIMS) would be beneficial in the separation of isomers and increase confidence in any assignment with the use of higher ion mobility resolution. Examples are given here where cIMS has been used to separate oxygenated metabolites of ranitidine and imipramine; this alternative separation mechanism adds to the separating power of UltraPerformance Liquid Chromatography (UPLC) and is of benefit when isomers co-elute.

## Benefits

- Leverage flexible resourcing as CCS values enable metabolite tracking across studies, species, and facilities using ion mobility-enabled instrumentation
- CCSOnDemand predicts CCS values, and it shows potential for assisting the structural elucidation of metabolites
- Differentiate isomeric metabolites with enhanced ion mobility resolution provided by cIMS

---

## Introduction

*In vitro* and *in vivo* metabolism studies are key elements during drug development. Typically, the level of complexity and study detail increases alongside drug development to address safety aspects with regards to human-specific or disproportionate metabolites and to identify metabolites contributing to pharmacological activity.

At the discovery stage, generic high-throughput liquid chromatography-mass spectrometry (LC-MS) methods with short gradients are used, focusing mainly on major metabolites to identify molecular liabilities within the potential drug candidate. In contrast, dedicated LC-MS methods with long gradients are used at development stage to provide chromatographic separation and structural elucidation of all observed metabolites to ensure safety coverage of any human metabolite in animal species as requested by health authorities.<sup>1,2</sup>

Conventionally, retention times and mass spectral data have been used to identify metabolites across species and studies. However, this can be problematic for closely eluting isomeric metabolites particularly if their MS/MS spectra are indistinguishable. Moreover, the order of elution may change depending on the chromatographic conditions used either internally or at an external service provider. Ion mobility-mass spectrometry (IMS) adds

another analytical dimension, enabling determination of the molecules' CCS value which is calculated from its drift time. This physiochemical property is analyte-specific and represents a robust parameter, allowing the tracking of metabolites across multiple platforms, various conditions, matrices, and studies as it is unaffected by these changes. In addition, the prediction of CCS values *via* computational techniques such as machine-learning or quantum mechanics is of great interest to aid in the structural identification of metabolites and derive their metabolic pathways.

Here, we compare CCS values for a series of approved drugs and their metabolites obtained using two different IMS enabled mass spectrometers (the SELECT SERIES Cyclic IMS and the SYNAPT G2-Si QTof), which were located in different facilities and operated by different scientists. Moreover, CCSDemand,<sup>3</sup> a machine-learning algorithm, was used to predict CCS values and compare theoretical with measured CCS values from each instrument. The cIMS technology was further used, providing increased IMS resolution, to distinguish isomeric metabolites, which was not possible on a commercially available linear IMS device.

---

## Experimental

### Sample Description

Reference standards of approved drugs and their metabolites (a total of 26 compounds) were first dissolved in dimethyl sulfoxide to obtain stock solutions at 1 mM. Working solutions at 10  $\mu$ M were subsequently prepared for each compound following dilution of each stock solution in acetonitrile/water (1/1, v/v), which were then used for analysis.

### Method Conditions

Predicted CCS values were obtained using CCSDemand, an experimental predictive machine-learning based algorithm.

Measured CCS values were determined following HDMS<sup>E</sup> analysis (n=3) either performed on a SYNAPT G2-Si QTof at Novartis (Basel, Switzerland) or a SELECT SERIES Cyclic IMS (single pass) at Waters (Wilmslow, UK). Corresponding LC-MS conditions are summarized below. In both cases, data acquisition was conducted with MassLynx (v4.2) whereas data processing was performed with UNIFI (v1.9.4) to determine measured CCS values. Arrival time distribution (ATD) plots were obtained using DriftScope (v3.0) and MassLynx (v4.2).

To further demonstrate the ability of cIMS to separate isomeric metabolites, mixtures of isomeric metabolites were infused into the ion source at 5  $\mu\text{L}/\text{min}$  and data were acquired using single and multiple passes.

## UPLC Conditions

UPLC systems:	Waters ACQUITY™ UPLC™ I Class <sup>a</sup>	Waters ACQUITY UPLC I-Class PLUS <sup>b</sup>
Vials:	LCMS certified total recovery vial (SKU: 600000671CV)	TruView™ LCMS certified max recovery vial (SKU: 186005662CV)
Column:	ACQUITY UPLC HSS T3, 2.1 × 150 mm, 1.8 $\mu\text{m}$ (SKU: 186003540)	ACQUITY UPLC HSS T3, 2.1 × 100 mm, 1.8 $\mu\text{m}$ (SKU: 186003539)
Column temperature:	40 °C	40 °C
Sample temperature:	Off	10 °C
Mobile phase A:	Water + 0.1% formic acid	Water + 0.1% formic acid
Mobile phase B:	Acetonitrile + 0.1% formic acid	Acetonitrile + 0.1% formic acid
Injection volume:	10 $\mu\text{L}$	1 $\mu\text{L}$

<sup>a</sup> Located at Novartis and coupled to a SYNAPT G2-S/ QTof

<sup>b</sup> Located at Waters and coupled to a SELECT SERIES Cyclic IMS

## Gradient Table

Time (min)	Flow (mL/min)	%A	%B	Curve
0.0	0.4	95	5	6
1.0	0.4	95	5	6
7.8	0.4	5	95	6
8.5	0.4	5	95	6
8.6	0.4	95	5	6
10.0	0.4	95	5	6

## MS Conditions

MS systems:	Waters SYNAPT G2-Si QTof	Waters SELECT SERIES Cyclic IMS
Ionization mode:	ESI+	ESI+
Capillary voltage:	3 kV	1 kV
Source temperature:	120 °C	120 °C
Cone voltage:	10 V	40 V
Cone gas flow:	20.0 L/h	20.0 L/h
Desolvation temperature:	350 °C	450 °C
Desolvation gas flow:	600 L/h	1000 L/h
Acquisition mode:	HDMS <sup>E</sup>	HDMS <sup>E</sup>
Analyzer:	Resolution mode (>25K FWHM)	Sensitivity mode (>60K FWHM)
Data format:	Continuum	Continuum
Mass range:	<i>m/z</i> 100–1200	<i>m/z</i> 50–1200
Collision energy ramp:	10 to 50 eV (Transfer region)	10 to 50 eV (Transfer region)
Scan time:	0.5 s	0.15 s

---

## Results and Discussion

Following triplicate analysis of a total of 26 compounds either on the SYNAPT G2-Si QTof or SELECT SERIES Cyclic IMS with MassLynx data acquisition, the HDMS<sup>E</sup> data were imported into UNIFI to determine their CCS values (Table 1). The root mean square error (RMSE) across all these measurements was 1.0% showing excellent agreement between the two data sets.

Compound	Predicted $^{TW}CCS_{N_2}$ ( $\text{\AA}^2$ ) <sup>a</sup>	Measured $^{TW}CCS_{N_2}$ ( $\text{\AA}^2$ ) <sup>b</sup>	Instrument deviation (%) <sup>c</sup>	Bias predicted versus measured (%) <sup>d</sup>
Ranitidine	169.2	166.8/167.8	-0.6	-1.4/-0.8
Ranitidine N-oxide	172.2	169.9/171.2	-0.8	-1.3/-0.6
Ranitidine S-oxide	175.2	167.3/171.8	-2.6	-4.5/-1.9
Ranitidine N,S-dioxide	176.4	170.8/168.0	-1.7	-3.2/-4.8
Imipramine	165.2	165.1/165.6	-0.3	-0.1/0.3
2-Hydroxyimipramine	171.9	169.4/169.7	-0.1	-1.4/-1.3
Imipramine N-oxide	169.6	169.0/170.0	-0.6	-0.4/0.2
10-Hydroxyimipramine	172.7	166.4/167.1	-0.4	-3.6/-3.3
Acetaminophen	130.6	128.0/130.5	-1.9	-2.0/-0.1
4-Acetaminophen sulfate	146.9	149.3/152.3	-2.0	1.6/3.7
Acetaminophen glutathione	202.1	200.4/201.8	-0.7	-0.9/-0.1
4-Acetaminophen $\beta$ -D-glucuronide	172.6	170.0/172.8	-1.6	-1.5/0.1
Diclofenac	157.0	156.7/158.1	-0.9	-0.2/0.7
4-Hydroxydiclofenac	164.9	161.5/162.2	-0.4	-2.0/-1.6
5-Hydroxydiclofenac	164.9	161.2/161.9	-0.4	-2.2/-1.8
Diclofenac acyl $\beta$ -D-glucuronide	197.5	207.3/202.2	2.6	5.0/2.4
Lansoprazole	177.2	179.2/180.3	-0.6	1.1/1.8
5-Hydroxylansoprazole	185.8	184.3/185.2	-0.5	-0.8 /-0.3
Lansoprazole sulfone	183.1	182.9/182.5	0.2	-0.1/-0.4
Lansoprazole sulfide	176.7	176.5/177.1	-0.3	-0.1/0.2
Alprenolol	160.3	158.2/159.9	-1.1	-1.3/-0.2
Atorvastatin	234.3	233.7/230.7	1.3	-0.3/-1.6
Clozapine	178.4	177.8/178.4	-0.4	-0.4/0.0
Clozapine N-oxide	181.7	180.0/181.2	-0.6	-0.9/-0.3
Duloxetine	169.4	168.7/171.3	-1.5	-0.4/1.1
4-Hydroxy-glucuronide duloxetine	212.6	207.6/207.5	0.1	-2.3/-2.4
RMSE			1.0	2.0/1.7

<sup>a</sup> Determined with CCSonDemand

<sup>b</sup> Mean value from triplicate analysis obtained with the SYNAPT G2-Si QToF/SELECT SERIES Cyclic IMS. The CVs were >0.9% and >0.1% for the SYNAPT G2-Si QToF and SELECT SERIES Cyclic IMS, respectively.

<sup>c</sup>  $100 \times (\text{SYNAPT G2-Si QToF} - \text{SELECT SERIES Cyclic IMS}) / \text{SELECT SERIES Cyclic IMS}$

<sup>d</sup>  $100 \times (\text{Measured} - \text{predicted}) / \text{predicted}$

Table 1. Comparison of predicted versus measured CCS values for 26 compounds obtained on the SYNAPT G2-Si or SELECT SERIES Cyclic IMS platform.

This excellent agreement in CCS values across both platforms for a wide range of approved drugs including their metabolites demonstrated the benefit of CCS values in addition to retention time and mass spectral data to track metabolites across different studies, methods, and facilities. The CCS value can be particularly useful when

product ion mass spectra observed for isomeric metabolites cannot be differentiated<sup>4,5</sup> and when retention times differ due to extended separation of new metabolites<sup>6</sup> or if LC conditions/equipment have been changed during drug development.

In addition, CCS values were predicted for all compounds using CCSONDemand. The difference between predicted and mean measured CCS values was within  $\pm 5.0\%$  for all 26 compounds regardless of the platform used. The calculated RMSE for the bias of 2.0% and 1.7% confirmed the ability to predict CCS values for certain metabolites. These predictions would not only aid in structure elucidation and better assign the localization of the biotransformation, but also allow the characterization of metabolic pathways more efficiently.

Moreover, the predicted CCS value can also give an indication of whether isomeric metabolites can be separated by ion mobility. For example, the predicted CCS value for ranitidine N- and S-oxide differed by  $3 \text{ \AA}^2$  as confirmed by the mean measured CCS values (Table 1). Assuming both isomeric metabolites would co-elute chromatographically and identical mass spectral as well as linear IMS data were obtained (similar to a single pass experiment with cIMS), the conclusion would have been that only one isomer existed. However, by extending the number of passes during cIMS analysis, which significantly increases IMS resolution,<sup>7</sup> both isomers could be separated as indicated in the corresponding ATD plots (Figure 1).




Figure 1. ATD plots of  $m/z$  331.1440  $[M+H]^+$  for ranitidine N- and S-oxide following 1 to 4 passes during cIMS analysis.

A similar situation was obtained with the oxygenated metabolites of imipramine (Figure 2). The predicted CCS for 2-hydroxyimipramine, imipramine N-oxide, and 10-hydroxyimipramine suggested that these isomeric metabolites may be separated using ion mobility. After single pass, the three isomers were not separated. However, 10-hydroxyimipramine could be observed as a shoulder following two passes with almost baseline resolution after four passes. The remaining two oxygenated metabolites could not be distinguished until two maxima were seen following 13 passes. To provide separation of the 2-hydroxyimipramine and imipramine N-oxide, 10-hydroxyimipramine was ejected from the cyclic array and the other two isomeric metabolites were separated by cIMS following 25 passes, resulting in a resolution of 325 ( $\Omega/\Delta\Omega$ ).




Figure 2. ATD plots of  $m/z$  297.1967  $[M+H]^+$  for oxygenated imipramine metabolites following 1 to 4, 13, and 25\* passes during cIMS analysis (\*after ejection of 10-hydroxyimipramine).

In general, the separation times used following multiple passes are compatible with UPLC separation as drift times after four passes are less than 100 ms and the loss in transmission with each pass (about 2.4%<sup>8</sup>) has minimal impact on the data. These multiple pass experiments can therefore be used in combination with UPLC to provide enhanced resolution over that provided by mass resolution alone.



---

## Conclusion

Regardless of the IMS platform (SYNAPT G2-Si QTof or SELECT SERIES Cyclic IMS), mean measured CCS values were identical and in agreement with predicted CCS values using the CCSonDemand machine-learning algorithm. Since CCS values are robust and analyte-specific, this physiochemical parameter can assist biotransformation scientists during drug discovery and development stage where various studies, facilities, and utilized analytical methods are involved. In particular, the usage of CCS values during metabolism studies will ease structural elucidation of identified isomeric metabolites-exhibiting similar retention times and mass spectral data. Moreover, metabolic pathways can be derived more efficiently by assigning the origin of metabolites based on relative CCS values, providing greater confidence in generated metabolism data.

Finally, accurately predicted CCS values act as an indicator to whether higher ion mobility resolution is required to separate isomeric metabolites. Here we demonstrated the need for an ion mobility resolution of up to 325 ( $\Omega/\Delta\Omega$ ) by using the unique multipass cyclic ion mobility capability of the SELECT SERIES Cyclic IMS for the separation of several isomeric metabolites throughout this study.

## Acknowledgements

The authors highly acknowledge the support from Markus Walles (Novartis), Mario Mergelsberg (Waters), and Emma Harry (Waters).

David Higton - Waters Corporation

Christian Lanshoeft, Frederic Lozac'h - Novartis Pharma AG.

---

## References

1. ICH M3 (R2) [Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals](https://www.ema.europa.eu/en/ich-m3-r2-non-clinical-safety-studies-conduct-human-clinical-trials-pharmaceuticals#current-effective-version-section) <<https://www.ema.europa.eu/en/ich-m3-r2-non-clinical-safety-studies-conduct-human-clinical-trials-pharmaceuticals#current-effective-version-section>> , 2013.
2. FDA Guidance for Industry. [Safety Testing of Drug Metabolites](https://www.fda.gov/regulatory) <<https://www.fda.gov/regulatory>-

[information/search-fda-guidance-documents/safety-testing-drug-metabolites>](#) , 2020.

3. Broeckling C, Yao L, Isaac G, Gioioso M, Ianchis V, Vissers JPC. Application of Predicted Collisional Cross Section to Metabolome Databases to Probabilistically Describe the Current and Future Ion Mobility Mass Spectrometry. *J Am Soc Mass Spectrom*, 2021, 32, 661–669.
4. Higton D, Palmer ME, Vissers JPC, Mullin LG, Plumb RS, Wilson ID. Use of Cyclic Ion Mobility Spectrometry (cIM)-Mass Spectrometry to Study the Intramolecular Transacylation of Diclofenac Acyl Glucuronide. *Anal Chem*, 2021, 93, 20, 7413–7421.
5. Connolly JFRB, Munoz-Muriedas J, Laphorn C, Higton D, Vissers JPC, Webb A, Beaumont C, Dear G.J. Investigation into Small Molecule Isomeric Glucuronide Metabolite Differentiation Using In Silico and Experimental Collision Cross-Section Values. *J. Am. Soc. Mass Spectrom.* 2021; 32 (8): 1976–1986.
6. Holdsworth C, Clayton R, Robinson H, Lord-Mears C, Kendrick J. Utilization of Ion Mobility Enabled Collisional Cross Section Measurements for the Comparison of Metabolites across Differing Chromatographic Methods. Poster DMDG 2016.
7. Giles K, Ujma J, Wildgoose J, Pringle S, Richardson K, Langridge D, Green M. A Cyclic Ion Mobility-Mass Spectrometry System. *Anal. Chem.* 2019, 91, 13, 8564–8573.

---

## Featured Products

[ACQUITY UPLC I-Class PLUS System <https://www.waters.com/134613317>](https://www.waters.com/134613317)

[SELECT SERIES Cyclic IMS <https://www.waters.com/waters/nav.htm?cid=135021297>](https://www.waters.com/waters/nav.htm?cid=135021297)

[SYNAPT G2-Si Mass Spectrometry <https://www.waters.com/134740653>](https://www.waters.com/134740653)

[Metabolite Identification Application Solution with UNIFI <https://www.waters.com/134682897>](https://www.waters.com/134682897)

[MassLynx MS Software <https://www.waters.com/513662>](https://www.waters.com/513662)

720007514, February 2022

© 2022 Waters Corporation. All Rights Reserved.